Six Genes Tied to AML Therapy Resistance Identified
Researchers pinpoint six genes that drive resistance to standard AML treatments, opening new avenues for targeted therapy against this deadly blood cancer.
A large-scale study has uncovered six genetic factors that make acute myeloid leukemia (AML) resistant to conventional therapy.
AML remains one of the most prevalent and lethal forms of blood cancer, with high relapse rates despite aggressive treatment regimens.
The newly identified genes could serve as biomarkers for prognosis and as targets for drugs designed to overcome resistance, potentially improving survival for patients.
Scientists say the findings pave the way for personalized treatment strategies and call for further clinical trials to validate the genes as therapeutic levers.
Темы
Автор
Анна Коршунова
корреспондент отдела экономики
Пишет о бюджетах, ценах и промышленности с 2016 года. Любит проверять заявления чиновников по открытым данным.
Все материалы автора